Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Cancers 2010, 2(2), 1166-1177; doi:10.3390/cancers2021166
Article

Different Serotonergic Expression in Nevomelanocytic Tumors

1
, 1
, 1
, 1
, 1
, 2
 and 1,*
Received: 7 April 2010; in revised form: 21 May 2010 / Accepted: 28 May 2010 / Published: 7 June 2010
View Full-Text   |   Download PDF [767 KB, uploaded 7 June 2010]   |   Browse Figures
Abstract: The neuromediator serotonin (5-hydroxytryptamine; 5-HT) has been proposed to play a role in tumor progression. Thus, the aim of the present investigation was to determine whether alterations in the serotonergic system occur in nevomelanocytic tumors. For this purpose, paraffin-embedded biopsies of superficial spreading malignant melanoma (SSM), dysplastic compound nevi (DN) and benign compound nevi (BCN) were characterized with regard to their expression of 5-HT, the 5-HT1A and 5-HT2A receptors, and the serotonin transporter protein (SERT), by immunohistochemical analysis. Melanocytes in the region surrounding the tumor were found to express both the 5-HT1A and 5-HT2A receptors. Tumor cells that immunostained positively for the different serotonergic markers were observed in the suprabasal epidermis of DN tissue and, to an even greater extent, in the case of SSM. Furthermore, some of these latter cells expressed both 5-HT1AR and 5-HT2AR. The level of expression of 5-HT1AR at the junctional area was lower for SSM than for DN or BCN. As the degree of atypia increased, the intensity of tumor cell staining in the dermis for 5-HT1AR and SERT declined. Vessel immunoreactivity for 5-HT2A was more intense in SSM than in BCN tissue. Round-to-dendritic cells that expressed both SERT and 5-HT1AR were seen to infiltrate into the dermal region of the tumor, this infiltration being more evident in the case of DN and SSM. These latter cells were also tryptase-positive, indicating that they are mast cells. Thus, alterations in serotonergic system may be involved in nevomelanocytic tumors and mast cells may play an important role in this connection.
Keywords: melanoma; serotonin; receptor; serotonin transporter protein; immunohistochemistry melanoma; serotonin; receptor; serotonin transporter protein; immunohistochemistry
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Naimi-Akbar, C.; Ritter, M.; Demel, S.; El-Nour, H.; Hedblad, M.-A.; Azmitia, E.C.; Nordlind, K. Different Serotonergic Expression in Nevomelanocytic Tumors. Cancers 2010, 2, 1166-1177.

AMA Style

Naimi-Akbar C, Ritter M, Demel S, El-Nour H, Hedblad M-A, Azmitia EC, Nordlind K. Different Serotonergic Expression in Nevomelanocytic Tumors. Cancers. 2010; 2(2):1166-1177.

Chicago/Turabian Style

Naimi-Akbar, Clara; Ritter, Markus; Demel, Sasika; El-Nour, Husameldin; Hedblad, Mari-Anne; Azmitia, Efrain C.; Nordlind, Klas. 2010. "Different Serotonergic Expression in Nevomelanocytic Tumors." Cancers 2, no. 2: 1166-1177.



Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert